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Accepted 29 March 2016; Published online 5 April 2016AbstractObjectives: The objective of our article is to show how ‘‘quality of evidence’’ and ‘‘imprecision,’’ as they are defined in Grading of
Recommendations Assessment, Development, and Evaluation (GRADE) articles, may lead to confusion. We focus only on the context of
systematic reviews.
Study Design and Setting: We analyze, with the aid of standard probabilistic and statistical concepts, the concepts of quality of ev-
idence and imprecision as used in the GRADE framework. This enables us to point out some weaknesses in the relation between ‘‘quality of
evidence’’ and ‘‘imprecision.’’
Results: The GRADE framework contains terms familiar from classical statistics, but these terms are used in nonstandard ways.
Notably, ‘‘imprecision’’ does not have the meaning in the GRADE framework that it has in statistics, and the well-known table of ‘‘evidence
levels’’ wrongly suggests that ‘‘quality of evidence’’ and ‘‘accuracy’’ express the same conceptdthey do not.
Conclusion: We believe that ‘‘conclusiveness’’ rather than ‘‘imprecision’’ would be a suitable term to use when the question whether
the CI excludes or includes certain critical margins is being addressed. Conclusiveness could also replace quality of evidence as the final
step for a systematic reviewer.  2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction deliver on its promises?And does it provide adequate supportGrading of Recommendations Assessment, Develop-
ment, and Evaluation (GRADE) is a framework for rating
quality of evidence and grading strength of recommenda-
tions. It is used as a tool for medicine, public health, and
health policy. The ultimate aim of GRADE is to provide
standardized clinical practice guidelines which address
alternative management options (www.gradeworking
group.org/). Many major healthcare organizations around
the world participate in the GRADE network, including
WHO, Cochrane, AHRQ, and NICE.
GRADE is a valuable tooldthere is no question about
that. But does it, in its present form, work well enough toConflict of interest: There are no conflicts of interest for any author of
the article.
* Corresponding author. Tel.: þ46 46 222 09 06.
E-mail address: niklas.vareman@med.lu.se (N. Vareman).
http://dx.doi.org/10.1016/j.jclinepi.2016.03.019
0895-4356/ 2016 The Authors. Published by Elsevier Inc. This is an open acc
licenses/by-nc-nd/4.0/).where the rating and standardization of evidential ratings of
intervention effects are concerned? These questions, we
believe, are especially interesting given that the GRADE
working group itself strongly recommends that there should
be a single, unified specification of GRADE because [1].ess arti.modifications may confuse some users of evidence
summaries. and because such changes compromise
the goal of a single system with which clinicians,
policy makers, and patients can become familiar.
(p. 391)In an effort to ensure that GRADE is not compromised,
a number of guideline articles [2] have been published in
the Journal of Clinical Epidemiology (JCE) (www.
guidelinedevelopment.org/handbook/). Yet, local modifica-
tions do occur. Indeed, through personal communication
with Professor Gordon Guyatt, we understand that thecle under the CC BY-NC-ND license (http://creativecommons.org/
Table 1. Elaboration of the four levels of evidence (modified table from
[3], p. 404, our emphases)
Quality level Definition
High We are very confident that the ‘‘true effect lies close
to that of the estimate of the effect’’
Moderate We are moderately confident in the effect estimate:
The ‘‘true effect is likely to be close to the estimate
of the effect, but there is a possibility that it is
substantially different’’
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tions of ‘‘quality of evidence.’’
The ‘‘purpose’’ of our article is to show how ‘‘quality of
evidence’’ and ‘‘imprecision,’’ as they are defined in
GRADE articles, may lead to serious confusion. We focus
only on the context of systematic reviews. We hope our
contribution will be useful in further conceptualizing
GRADE’s definition of quality of evidence.Low Our confidence in the effect estimate is limited:
The ‘‘true effect may be substantially different
from the estimate of the effect’’
Very low We have very little confidence in the effect estimate:
The ‘‘true effect is likely to be substantially
different from the estimate of the effect’’2. The GRADE process
In GRADE, quality of evidence is not determined via an
algorithm designed to calculate specific evidential values.
GRADE is intended to facilitate a systematic and transparent
process. Crucial decisions are documented throughout this
process, and this allows those considering the evidence to
assess each step and decide whether to accept or reject
the final rating. Unanimous agreement on the final rating is
not guaranteed, however, and transparency seems to be
just as important as consistency in quality rating [3].
The crucial decisions just mentioned can rate the level of
evidence presented in a study down or up. Study design de-
termines the initial rating in the process: lack of randomiza-
tion in nonrandomized studies will lead to default
downgrading by two levels unless no downgrading can be
clearly and transparently justified by the fact that other
measures to protect against bias and confounding that
resemble randomization were observed. According to
GRADE, this initial rating may be changed for any of eight
specific reasons, five of which lower the rating and three of
which raise it [3]. Rating down may follow from (1) study
limitations, (2) inconsistency, (3) indirectness, (4) impreci-
sion, or (5) publication bias. Rating up primarily concerns
non-randomized studies. It may reflect (6) the magnitude
of an effect, (7) the dose-response gradient, or (8) the fact
that all plausible confounding would either reduce the
demonstrated effect or increase the effect if no effect was
observed. The outcome of this process, for the systematic
reviewer, is a quality rating for every single outcome: high,
moderate, low, or very low.Table 2. Rule for rating downdsystematic reviews (modified from [5]
p. 4, our emphases)
If the optimal information size [OIS] criterion is not met, rate down for
imprecision, unless the sample size is very large (n  2,000 [The
limit ‘‘200 or perhaps 4,000 patients’’ is stated in the GRADE
article [5], but we believe that 2,000 patients is the intended
number.] to 4,000 patients [It is not clear whether the criterion for
exclusion and nonexclusion of critical margins (including ‘‘no
effect’’) applies when N  2,000 (or 4,000) is met.]).
If the ‘‘OIS criterion’’ is met and the 95% CI excludes no effect.
precision adequate
If OIS is met, and CI overlaps no effect. rate down if CI fails to
exclude ‘‘important benefit or important harm’’
Abbreviation: CI, confidence interval.3. Quality of evidence
According to GRADE, quality of evidence in a system-
atic review is defined as follows [3]: ‘‘.the ratings of the
quality of evidence reflect the extent of our confidence that
the estimates of the effect are correct.’’ It is obvious that
quality of evidence is a property of the beholders, the sys-
tematic reviewers, and not of the research results as such.
Furthermore, that quality (or level of confidence) is under-
stood as a continuous variable [4] but is communicated on a
four-part ordinal scale (Table 1).
The verbal expressions in Table 1 suggest that a ‘‘correct
estimate’’ is understood as an estimate that ‘‘lies close’’ to
the ‘‘true effect’’ (the parameter value). The quality of
evidence, therefore, appears to be the reviewers’ degreeof confidence in the closeness of a parameter value to an
estimated value.
4. Imprecision
Imprecision is one of five reasons for rating down
evidential quality [5]. For systematic reviewers, the concept
of imprecision includes several components: absolute sam-
ple size, a retrospective statistical power calculation (p. 5)
called optimal information size (OIS), confidence intervals
(CI), and critical margins regarding ‘‘no effect,’’ ‘‘impor-
tant benefit,’’ and ‘‘important harm.’’ This is expressed in
Table 2 as a rule for rating down quality of evidence.
GRADE imprecision is thus a combination of more than
one aspect of statistical power, confidence intervals, and
specified limits (in other words, critical margins).
5. The problem
The problem is that ‘‘imprecision’’ includes a compo-
nent that obviously does not affect the closeness of the
parameter value to the estimatednamely, assessment of
whether the CI excludes certain critical margins. This prob-
lem is demonstrated in Fig. 1.
Assume that the OIS criterion is met for both results A
and B. A excludes ‘‘no effect,’’ whereas B includes it.
Therefore, the systematic reviewer should rate down for
imprecision in case B, but not in case A.
Fig. 1. Inclusion of ‘‘no effect’’ (hypothetical results). (Point estimate
is symbolized by a black square; CI is symbolized by a vertical line.)
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systematic reviewer should be very confident that the
parameter value in case A lies close to the estimate. In case
B, the reviewer should be (possibly) moderately convinced
that the parameter value lies close to the estimatedin other
words, he or she should be less confident in case B than in
case A. In both cases, we assume that there are no other
reasons for rating down the quality of evidence. Now,
observe that the CI is longer in case A than it is in B. It
is obviously confusing that the reviewer should have more
trust in the closeness in case A than he or she does in B.
The introduction of ‘‘important benefit’’ and ‘‘important
harm’’ gives rise to the same kind of problem. In Fig. 2,
there are four hypothetical results (C to F). We symbolize
‘‘margin of important harm’’ by D and ‘‘margin of impor-
tant benefit’’ by Dþ. Within region R, the effects are so
small that they are of no clinical relevance.
Assume that the OIS criterion is met in all of C to F. The
precision of C is adequate already at step 2 in Table 2, since
‘‘no effect’’ is excluded. Results D, E, and F, on the other,
hand are candidates for rating down. Since D and E exclude
D, precision here is adequate according to GRADE. F,
however, is rated down on the basis of imprecision
(Table 2). The CI for C and for D is longer than it is for
F. Does this mean that the systematic reviewer should be
more convinced that the estimate in C and D lies close to
the parameter value than her or she is in case F? Confusion
may arise as to what measure to use.6. Conceptual sources of confusion
The GRADE framework contains terms familiar from
classical statistics, but these terms are used in nonstandardFig. 2. Inclusion of important ‘‘benefit’’ and ‘‘harm’’ (hypothetical
results).ways. Notably, ‘‘imprecision’’ does not have the meaning in
the GRADE framework that it has in statistics. Adding to
the confusion, the concept of imprecision deployed in the
GRADE framework is not well defined. Another problem
is that the well-known table of ‘‘evidence levels’’ wrongly
suggests that ‘‘quality of evidence’’ and ‘‘accuracy’’
express the same conceptdthey do not.
In statistics [6], ‘‘accuracy’’ is a familiar concept ex-
pressing closeness between a parameter value and an esti-
mate; it encompasses both bias and sample precision
(p. 267e9). This can be illustrated by using the idea of
an arithmetic mean. Thus, bias, in this particular case, is ex-
pressed as the difference between the expected sample
mean and population mean (Equation 1).bias 5EðxÞ  mx ð1Þ
Sample precision is then the variance of the observations
about the sample mean (Equation 2).sample precision 5 s2x5
1
n 1$
Xn
i51
ðxi xÞ2 ð2ÞThe combination of sample precision and bias can,
accordingly, be calculated as in Equation 3 (provided that
there is available information indicating bias).accuracy 5
1
n 1$
Xn
i51
ðxi ðx biasÞÞ2 ð3ÞFinally, accuracy can be simplified as in Equation 4 by
substituting mx for ðx biasÞ.accuracy 5
1
n 1$
Xn
i51
ðxi mxÞ2 ð4ÞIn this example, bias, precision, and accuracy are all
explicitly expressed, and the relationships between the con-
cepts are clear.
The notion of quality of evidence formulated in GRADE
guideline articles is reminiscent of accuracy. The closeness
of a parameter value to an estimate is clearly indicated in
Table 1 above, but the quality of evidence is not explicitly
defined, so we cannot be sure what it is. GRADE impreci-
sion is more difficult to understand from a statistical point
of view, since it is based on 3e4 components, as we
described previously. The content of the concepts is
verbally indicated by the decision rule stated in Table 2.
The relationship of ‘‘imprecision’’ to ‘‘quality of evidence’’
is unfortunately not explicitly explained.
In practice, we are often faced with a CI calculated on
the assumption that there is no bias present, although we
suspect that the sample mean x and the sample variation
s2x are biased to some degree. A biased x implies that the
point estimate is too high or too low in comparison to mx,
and also that the limits of the CI are either too high or
too low. A biased s2x entails that the CI is too long or too
short [CI is x ta=2,sx  mx  xþ ta=2,sx. Length depends
Fig. 3. Two alternative conceptual approaches. CI, confidence interval; OIS, optimal information size.
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to sx5
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2x=n
p
. Calculation assumes Eðs2xÞ5s2x : Possible
bias Eðs2xss2xÞ.]. This means that there are uncertainties
not captured by the CI.
We believe the GRADE framework has great potential
when we try to understand and assess biases in x and s2x . The
reasons for rating down or up address such biases more or less
clearly, but explicit definitions and specifications are needed.
If we have reasonable knowledge of the size and direc-
tion of bias, the CI can be adjusted accordingly. If we do
not, the identified biases can be treated as uncertainty fac-
tors that may either be included in a model [7] or ap-
proached using the GRADE rates: rate 4 for minimal
uncertainty and rate 1 for maximal uncertainty.7. A procedural source of confusion
We think that critical margins are included in impreci-
sion too early in the evaluation process presented in
contemporary GRADE. It would be preferable for the com-
parison of a CI with critical margins to be preceded by the
assessment of accuracy.
In Fig. 3, the GRADE approach is compared with an
alternative. In GRADE, confidence in the closeness of a
parameter value to an estimate (quality of evidence) is pre-
ceded by a consideration of the eight possible reasons for
rating down or up, including imprecision (with the inclusion
or exclusion of critical margins). In this alternative
approach, closeness (accuracy) is based on bias and preci-
sion. Once accuracy has been determined, the (possibly)
adjusted CIs are compared with the critical margins. This
is a standard procedure for dealing with uncertainties (Seefor example, ISO 17025 [www.iso.org/iso/home.html] and
Guide to the Expression of Uncertainty in Measurement
[GUM; www.bipm.org/en/publications/guides/gum.html].)
and the compliance with quality margins specified by deci-
sion makers and stake holders; a common term for such
margins is ‘‘tolerance frames’’ or levels [8]. First, there is
an evaluationdand statementdof uncertainty; there fol-
lows a comparison of adjusted CIs with tolerance levels.8. Suggestions
We think ‘‘conclusiveness’’ rather than ‘‘imprecision’’
would be a suitable term to use when the question whether
the CI excludes or includes certain critical margins is being
addressed. Conclusiveness could also replace quality of ev-
idence as the final step for a systematic reviewer.
This suggestion is in line with the conceptual framework
of noninferiority and equivalence trials [9]. In noninferior-
ity trials, the critical noninferiority margin is introduced,
not as an aspect of imprecision, but as a support for deci-
sion making. When noninferiority margin is included, the
result is called inconclusive. When it is not, the result is
conclusive and either noninferior or inferior.
Finally, ‘‘accuracy’’ is a better term than ‘‘quality of ev-
idence’’ when closeness is being addressed.9. Concluding remarks
Our analysis suggests that in the GRADE guideline arti-
cles the key notions of ‘‘quality of evidence’’ and ‘‘impre-
cision’’ are, independently, but especially when taken
5S. Anttila et al. / Journal of Clinical Epidemiology 75 (2016) 1e5together, a source of serious confusion, and that this may
impede the practical process of evidence formation.
Explicit GRADE guidance is therefore required here.
Several other issues in the GRADE guidance need to be
discussed, but not here. Possibly the most important issue
concerns the difference between evaluating evidence in a
systematic review and giving guidelines [10], and specif-
ically the question how an evidential value is to be trans-
formed into a value used for regulatory purposes.
A separate issue arises because second-order uncertainty
seems to be introduced in the GRADE approach [11,12] as
a result of ‘‘quality of evidence’’ being interpreted in
GRADE as referring to the assessor’s epistemic confidence
in the CI. It is important to distinguish between different
types of uncertainty occurring at different stages in the
GRADE process. A third issue focuses on the translation
of quality of evidence from a continuous to an ordinal level
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